Ritonavir
Norvir (ritonavir) is a small molecule pharmaceutical. Ritonavir was first approved as Norvir on 1996-03-01. It is used to treat acquired immunodeficiency syndrome in the USA. It has been approved in Europe to treat HIV infections. The pharmaceutical is active against cytochrome P450 3A4, Gag-Pol, and Gag-Pol polyprotein. In addition, it is known to target UDP-glucuronosyltransferase 1A1, cytochrome P450 2D6, cytochrome P450 1A2, cytochrome P450 2C9, cytochrome P450 2C19, cytochrome P450 2B6, ATP-dependent translocase ABCB1, and cytochrome P450 2C8.
| Trade Name | Norvir |
|---|---|
| Common Name | Ritonavir |
| ChEMBL ID | CHEMBL163 |
| Indication | acquired immunodeficiency syndrome, hiv infections |
| Drug Class | Antivirals: HIV protease inhibitors (saquinavir type) |
